NextCure, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
NextCure filed an 8-K on 2026-10-30 disclosing Item 5.02 events (departure of directors/officers and compensatory arrangements). The filing text provided does not include the actual substantive disclosures—only the header, metadata, and document structure. Specific names, departure dates, compensation amounts, and arrangement details are not available in this excerpt.
Why this rating
Officer/director changes are routine disclosures. Without specifics on role, replacement status, or compensation impact relative to $12.6M market cap, cannot assess materiality. Likely administrative.
Extracted items
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.